Antibacterial peptides and proteins with multiple cellular targets

Journal of Peptide Science

Volumn 11, Issue 11, 2005, Pages 697-706

  Otvos Jr , Laszlo ^a  

^a OLPE LLC   (United States)

Author keywords

Antimicrobial peptide; Bacterial membrane; Cell penetration; Enzyme inhibition; Host defense; Immunostimulatory; Protein folding

Indexed keywords

ANGIOGENIN; ANTIMICROBIAL CATIONIC PEPTIDE; APIDAECIN 1A; ATTACIN C; AZUROCIDIN; BACTERIOCIN; BETA DEFENSIN 2; BUFORIN DERIVATIVE; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CATHEPSIN; CECROPIN; DERMASEPTIN; DROCOSIN; EPIDERMIN; GAEGURIN; INDOLICIN; LACTOFERRIN; LANTIBIOTIC; MAGAININ DERIVATIVE; MICROCIN; MICROCIN B17; NISIN; PHEROMONE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; PR 39; PROADRENOMEDULLIN; RAMOPLANIN; TEMPORIN A; THROMBIN INDUCED PLATELET MICROBICIDAL PROTEIN 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL MEMBRANE; CARBOXY TERMINAL SEQUENCE; CELL PERMEABILIZATION; CELL SURFACE; CONCENTRATION RESPONSE; DNA SYNTHESIS INHIBITION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HOST RESISTANCE; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; KIDNEY CLEARANCE; MEMBRANE BINDING; MINIMUM INHIBITORY CONCENTRATION; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN INTERACTION; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; TARGET CELL;

ANIMALS; ANTI-BACTERIAL AGENTS; PEPTIDES; PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

BACTERIA (MICROORGANISMS); MAMMALIA;

EID: 28044443162     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/psc.698     Document Type: Review

References (102)

1. Meister M, Lemaitre B, Hoffmann JA. Antimicrobial peptide defense in Drosophila. BioEssays 1997; 19: 1019-1026.
2. Gallo RL, Huttner EM. Antimicrobial peptides: an emerging concept in cutaneous biology. J. Invest. Dermatol. 1998; 111: 739-743.
3. Hiemstra PS, Fernie-King BA, McMichael J, Lachmann PJ, Sallenave JM. Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics. Curr. Pharm. Des. 2004; 10: 2891-2905.
4. Hancock RE, Scott MG. The role of antimicrobial peptides in animal defenses. Proc. Natl. Acad. Sci. U.S.A. 2000; 97: 8856-8861.
5. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-395.
6. Bush K, Macielag M, Weidner-Wells M. Taking inventory: antibacterial agents currently at or beyond phase I. Curr. Opin. Microbiol. 2004; 7: 466-476.
7. Ge Y, MacDonald DL, Holroyd KJ, Thornsberry C, Wexler H, Zasloff M. In vitro properties of pexiganan, an analog of magainin. Antimicrob. Agents Chemother. 1999; 43: 782-788.
8. Loffet A. Peptides as drugs: is there a market? J. Pept. Sci. 2002; 8: 1-7.
9. Amsterdam D. Susceptibility testing of antimicrobials in liquid media. In Antibiotics in Laboratory Medicine, Loman V (ed.). Williams and Wilkins: Philadelphia, 1996; 52-111.
10. Mak P, Wojcik K, Silberring J, Dubin A. Antimicrobial peptides derived from heme-containing proteins: hemocidins. Antonie Van Leeuwenhoek 2000; 77: 197-207.
11. Bush K. Antibacterial drug discovery in the 21st century. Clin. Microbiol. Infect. 2004; 10(Suppl. 4): 10-17.
12. Duclohier H, Molle G, Spach G. Antimicrobial peptide magainin I from Xenopus skin forms anion-permeable channels in planar lipid bilayers. Biophys. J. 1989; 56: 1017-1023.
13. Christensen B, Fink J, Merrifield RB, Mauzerall D. Channel-forming properties of cecropins and related model compounds incorporated into planar lipid membranes. Proc. Natl. Acad. Sci. U.S.A. 1988; 85: 5072-5076.
14. Lehrer RI, Barton A, Daher KA, Harwig SSL, Ganz T, Selsted ME. Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J. Clin. Invest. 1989; 84: 553-561.
15. Shai Y. Molecular recognition between membrane-spanning polypeptides. Trends Biochem. Sci. 1995; 20: 460-464.
16. Matsuzaki K, Mitani Y, Akada KY, Murase O, Yoneyama S, Zasloff M, Miyajima K. Mechanism of synergism between antimicrobial peptides magainin 2 and PGLa. Biochemistry 1998; 37: 15144-15153.
17. Chaturvedi PR, Decker CJ, Odinecs A. Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. Curr. Opin. Chem. Biol. 2001; 5: 452-463.
18. Futaki S, Goto S, Suzuki T, Nakase I, Sugiura Y. Structural variety of membrane permeable peptides. Curr. Protein Pept. Sci. 2003; 4: 87-96.
19. Briolat J, Wu SD, Mahata SK, Gonthier B, Bagnard D, Chasserot-Golaz S, Belle KB, Aunis D, Metz-Boutigue MH. New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A. Cell. Mol. Life Sci. 2005; 62: 377-385.
20. Otvos L Jr, Cudic M, Chua BY, Deliyannis G, Jackson DC. An insect antibacterial peptide-based drug delivery system. Mol. Pharmaceut. 2004; 1: 220-232.
21. Lau YE, Rozek A, Scott MG, Goosney DL, Davidson DJ, Hancock RE. Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells. Infect Immun. 2005; 73: 583-591.
22. Cudic M, Otvos L Jr. Intracellular targets of antibacterial peptides. Curr. Drug Targets 2002; 3: 101-106.
23. Bulet P, Stocklin R. Insect antimicrobial peptides: structures, properties and gene regulation. Protein Pept. Lett. 2005; 12: 3-11.
24. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 2005; 3: 238-250.
25. Park CB, Kim HS, Kim SC. Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem. Biophys. Res. Commun. 1998; 244: 253-257.
26. Park CB, Kim MS, Kim SC. A novel antimicrobial peptide from bufo bufo gargarizans. Biochem. Biophys. Res. Commun. 1996; 218: 408-413.
27. Park CB, Yi K, Matsuzaki K, Kim MS, Kim SC. Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II. Proc. Natl. Acad. Sci. U.S.A. 2000; 97: 8245-8250.
28. Zhang L, Benz R, Hancock RE. Influence of proline residues on the antibacterial and synergistic activities of alpha-helical peptides. Biochemistry 1999; 38: 8102-8111.
29. Xiong Y, Yeaman MR, Bayer AS. In vitro antibacterial activities of platelet microbicidal protein and neutrophil defensin against Staphylococcus aureus are influenced by antibiotics differing in mechanism of action. Antimicrob. Agents Chemother. 1999; 43: 1111-1117.
30. Koo SP, Bayer AS, Yeaman MR. Diversity in antistaphylococcal mechanisms among membrane-targeting antimicrobial peptides. Infect. Immun. 2001; 69: 4916-4922.
31. Patrzykat A, Friedrich CL, Zhang L, Mendoza V, Hancock RE. Sublethal concentrations of pleurocidin-derived antimicrobial peptides inhibit macromolecular synthesis in Escherichia coli. Antimicrob. Agents Chemother. 2002; 46: 605-614.
32. Castle M, Nazarian A, Yi S-S, Tempst P. Lethal effects of apidaecin on Escherichia coli involve sequential molecular interactions with diverse targets. J. Biol. Chem. 1999; 274: 32555-32564.
33. Otvos L Jr, O I, Rogers ME, Consolvo PJ, Condie BA, Lovas S, Bulet P, Blaszczyk-Thurin M. Interaction between heat shock proteins and antimicrobial peptides. Biochemistry 2000; 39: 14150-14159.
34. Kragol G, Lovas S, Varadi G, Condie BA, Hoffmann R, Otvos L Jr. The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry 2001; 40: 3016-3026.
35. Otvos L Jr, Snyder C, Condie B, Bulet P, Wade JD. Chimeric antimicrobial peptides exhibit multiple modes of action. Int. J. Pept. Res. Ther. 2005; 11: 29-42.
36. Kragol G, Hoffmann R, Chattergoon MA, Lovas S, Cudic M, Bulet P, Condie BA, Rosengren KJ, Montaner LJ, Otvos L Jr. Identification of crucial residues for the antibacterial activity of the proline-rich peptide, pyrrhocoricin. Eur. J. Biochem. 2002; 269: 4226-4237.
37. Ginsburg I. Bactericidal cationic peptides can also function as bacteriolysis-inducing agents mimicking beta-lactam antibiotics? It is enigmatic why this concept is consistently disregarded. Med. Hypotheses 2004; 62: 367-374.
38. Brotz H, Josten M, Wiedemann I, Schneider U, Gotz F, Bierbaum G, Sahl HG. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol. Microbiol. 1998; 30: 317-327.
39. McCafferty DG, Cudic P, Yu MK, Behenna DC, Kruger R. Synergy and duality in peptide antibiotic mechanisms. Curr. Opin. Chem. Biol. 1999; 3: 672-680.
40. Adams SA, Subramanian V. The angiogenins: an emerging family of ribonuclease related proteins with diverse cellular functions. Angiogenesis 1999; 3: 189-199.
41. Hooper LV, Stappenbeck TS, Hong CV, Gordon JI. Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat. Immunol. 2003; 4: 269-273.
42. Aisen P, Listowsky I. Iron transport and storage proteins. Annu. Rev. Biochem. 1980; 49: 357-393.
43. Arnold RR, Cole MF, McGhee JR. A bacteriocidal effect for human lactoferrin. Science 1977; 197: 263-265.
44. Furmanski P, Li Z-P, Furtuna MB, Swamy CVB, Das MR. Multiple molecular forms of human lactoferrin. Identification of a class of lactoferrins that possess ribonuclease activity and lack iron-binding capacity. J. Exp. Med. 1989; 170: 415-429.
45. Chi-Zhang Y, Yam KL, Chikindas ML. Effective control of Listeria monocytogenes by combination of nisin formulated and slowly released into a broth system. Int. J. Food Microbiol. 2004; 90: 15-22.
46. Kleerebezem M. Quorum sensing control of lantibiotic production; nisin and subtilin autoregulate their own biosynthesis. Peptides 2004; 25: 1405-1414.
47. Sturme MH, Kleerebezem M, Nakayama J, Akkermans AD, Vaugha EE, de Vos WM. Cell to cell communication by autoinducing peptides in gram-positive bacteria. Antonie Van Leeuwenhoek 2002; 81: 233-243.
48. van Kraaij C, Breukink E, Noordermeer MA, Demel RA, Siezen RJ, Kuipers OP, de Kruijff B. Pore formation by nisin involves translocation of its C-terminal part across the membrane. Biochemistry 1998; 37: 16033-16040.
49. Patrzykat A, Douglas SE. Antimicrobial peptides: cooperative approaches to protection. Protein Pept. Lett. 2005; 12: 19-25.
50. Bals R, Wilson JM. Cathelicidins - a family of multifunctional antimicrobial peptides. Cell. Mol. Life Sci. 2003; 60: 711-720.
51. Eckman L. Defense molecules in intestinal innate immunity against bacterial infections. Curr. Opin. Gastroenterol. 2005; 21: 147-151.
52. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J. Leukoc. Biol. 2004; 75: 39-48.
53. Agerberth B, Charo J, Werr J, Olsson B, Idali F, Lindbom L, Kiessling R, Jornvall H, Wigzell H, Gudmundsson GH. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000; 96: 3086-3093.
54. Braff MH, Hawkins MA, Nardo AD, Lopez-Garcia B, Howell MD, Wong C, Lin K, Streib JE, Dorschner R, Leung DYM, Gallo RL. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J. Immunol. 2005; 174: 4271-4278.
55. Li J, Post M, Volk R, Gao Y, Li M, Metais C, Sato K, Tsai J, Aird W, Rosenberg RD, Hampton TG, Sellke F, Carmeliet P, Simons M. PR39, a peptide regulator of angiogenesis. Nat. Med. 2000; 6: 49-55.
56. Shi J, Ross CR, Chengappa MM, Sylte MJ, McVey DS, Blecha F. Antibacterial activity of a synthetic peptide (PR-26) derived from PR-39, a proline-arginine-rich neutrophil antimicrobial peptide. Antimicrob. Agents Chemother. 1996; 40: 115-121.
57. Chan YR, Zanetti M, Gennaro R, Gallo RL. Anti-microbial activity and cell binding are controlled by sequence determinants in the anti-microbial peptide PR-39. J. Invest. Dermatol. 2001; 116: 230-235.
58. Subbalakshmi C, Sitaram N. Mechanism of antimicrobial action of indolicidin. FEMS Microbiol. Lett. 1998; 160: 91-96.
59. Salomon RA, Farias RN. Microcin 25, a novel antimicrobial peptide produced by Escherichia coli. J. Bacteriol. 1992; 174: 7428-7435.
60. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J. Immunol. 2002; 169: 3883-3891.
61. Gao Y, Lecker S, Post MJ, Hietaranta AJ, Li J, Volk R, Li M, Sato K, Saluja AK, Steer ML, Goldberg AL, Simons M. Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J. Clin. Invest. 2000; 106: 439-448.
62. Bowdish DM, Davidson DJ, Hancock RE. Re-evaluation of the role of host defence peptides in mammalian immunity. Curr. Protein Pept. Sci. 2005; 6: 35-51.
63. Schroder JM. Epithelial peptide antibiotics. Biochem. Pharmacol. 1999; 15: 121-134.
64. Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, Anderson M, Schroder JM, Wang JM, Howard OM, Oppenheim JJ. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999; 286: 525-528.
65. Niyonsaba F, Ogawa H, Nagaoka I. Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils. Immunology 2004; 111: 273-281.
66. Niyonsaba F, Iwabuchi K, Matsuda H, Ogawa H, Nagaoka I. Epithelial cell-derived human beta-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway. Int. Immunol. 2002; 14: 421-426.
67. Lillard JW Jr, Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR. Mechanisms for induction of acquired host immunity by neutrophil peptide, defensins. Proc. Natl. Acad. Sci. U.S.A. 1999; 96: 651-656.
68. Tani K, Murphy WJ, Chertov O, Salcedo, R, Koh CY, Utsunomiya I, Funakoshi S, Asai O, Herrmann SH, Wang JM, Kwak LW, Oppenheim JJ. Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int. Immunol. 2000; 12: 691-700.
69. Oppenheim JJ, Biragyn A, Kwak LW, Yang D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann. Rheum. Dis. 2003; 62(Suppl. 2): 17-21.
70. Biragyn A, Surenhu M, Yang D, Ruffini PA, Haines BA, Klyushnenkova E, Oppenheim JJ, Kwak LW. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J. Immunol. 2001; 167: 6644-6653.
71. Yang D, Biragyn A, Kwak LW, Oppenheim JJ. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol. 2002; 23: 291-296.
72. Park JM, Jung JE, Lee BJ. Antimicrobial peptides from the skin of a Korean frog, Rana rugosa. Biochem. Biophys. Res. Commun. 1994; 205: 948-954.
73. Kim S, Kim SS, Bang YJ, Kim SJ, Lee BJ. In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides 2003; 24: 945-953.
74. Shin SY, Lee SH, Yang ST, Park EJ, Lee DG, Lee MK, Eom SH, Song WK, Kim Y, Hahm KS, Kim JI. Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs. J. Pept. Res. 2001; 58: 504-514.
75. Bezault J, Bhimani R, Wiprovnick J, Furmanski P. Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res. 1994; 54: 2310-2312.
76. Aguilera O, Quiros LM, Fierro JF. Transferrins selectively cause ion efflux through bacterial and artificial membranes. FEBS Lett. 2003; 548: 5-10.
77. Swart PJ, Kuipers EM, Smit C, Van Der Strate BW, Harmsen MC, Meijer DK. Lactoferrin. Antiviral activity of lactoferrin. Adv. Exp. Med. Biol. 1998; 443: 205-213.
78. Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J. Appl. Bacteriol. 1992; 73: 472-479.
79. Gabay JE. Antimicrobial proteins with homology to serine proteases. Ciba Found Symp. 1994; 186: 237-247.
80. Watorek W. Azurocidin - inactive serine proteinase homolog acting as a multifunctional inflammatory mediator. Acta Biochim. Pol. 2003; 50: 743-752.
81. Heinzelmann M, Kim E, Hofmeister A, Gordon LE, Platz A, Cheadle WG. Heparin binding protein (CAP37) differentially modulates endotoxin-induced cytokine production. Int. J. Surg. Investig. 2001; 2: 457-466.
82. McCabe D, Cukierman T, Gabay JE. Basic residues in azurocidin/HBP contribute to both heparin binding and antimicrobial activity. J. Biol. Chem. 2002; 277: 27477-27488.
83. Marutsuka K, Hatakeyama K, Sato Y, Yamashita A, Sumiyoshi A, Asada Y. Immunohistological localization and possible functions of adrenomedullin. Hypertens. Res. 2003; 26: S33-S40.
84. Marutsuka K, Nawa Y, Asada Y, Hara S, Kitamura K, Eto T, Sumiyoshi A. Adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP) are present in human colonic epithelia and exert an antimicrobial effect. Exp. Physiol. 2001; 86: 543-545.
85. Kobayashi H, Yanagita T, Yokoo H, Wada A. Adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP) in adrenal chromaffin cells. Peptides 2001; 22: 1895-1901.
86. 2+ dependent, agonist-stimulated secretion of human adrenal glands. Hypertension 1999; 33: 1185-1189.
87. Takei Y, Hyodo S, Katafuchi T, Minamino N. Novel fish-derived adrenomedullin in mammals: structure and possible function. Peptides 2004; 25: 1643-1656.
88. Allaker RP, Kapas S. Adrenomedullin and mucosal defence: interaction between host and microorganism. Regul. Pept. 2003; 112: 147-152.
89. Chen Q, Wade D, Kurosaka K, Wang ZY, Oppenheim JJ, Yang D. Temporin A and related frog antimicrobial peptides use formyl peptide receptor-like 1 as a receptor to chemoattract phagocytes. J. Immunol. 2004; 173: 2652-2659.
90. Yan H, Hancock RE. Synergistic interactions between mammalian antimicrobial defense peptides. Antimicrob. Agents Chemother. 2001; 45: 1558-1560.
91. 2 against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. Peptides 2003; 24: 1315-1318.
92. Chambers HF. Solving staphylococcal resistance to β-lactams. Trends Microbiol. 2003; 11: 145-148.
93. Patrzykat A, Zhang L, Mendoza V, Iwama GK, Hancock RE. Synergy of histone-derived peptides of coho salmon with lysozyme and flounder pleurocidin. Antimicrob. Agents Chemother. 2001; 45: 1337-1342.
94. Rabel D, Charlet M, Ehret-Sabatier L, Cavicchioli L, Cudic M, Otvos L Jr, Bulet P. Primary structure and in vitro antibacterial properties of the Drosophila melanogaster attacin C Pro-domain. J. Biol. Chem. 2004; 279: 14853-11489.
95. Singh PK, Tack BF, McCray PB Jr, Welsh MJ. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am. J. Physiol. Lung Cell Mol. Physiol. 2000; 279: L799-L805.
96. Cudic M, Lockatell CV, Johnson DE, Otvos L Jr. In vitro and in vivo activity of a designed antibacterial peptide analog against uropathogens. Peptides 2003; 24: 807-820.
97. Terasaki T, Deguchi Y, Sato H, Hirai K, Tsuji A. In vivo transport of a dynorphin-like analgesic peptide, E-2078, through the blood-brain barrier: an application of brain microdialysis. Pharm. Res. 1991; 8: 815-820.
98. Shimura T, Tabata S, Ohnishi T, Terasaki T, Tsuji A. Transport mechanism of a new behaviorally highly potent adrenocorticotropic hormone (ACTH) analog, ebiratide, through the blood-brain barrier. J. Pharmacol. Exp. Ther. 1991; 258: 459-465.
99. Pardridge WM, Triguero D, Buciak JL, Yang J. Evaluation of cationized rat albumin as a potential blood-brain drug transport vector. J. Pharmcol. Exp. Ther. 1990; 255: 893-899.
100. Lupetti A, Welling MM, Pauwels EKJ, Nibbering PH. Radiolabeled antimicrobial peptides for infection detection. Lancet Infect. Dis. 2003; 3: 233-239.
101. Otvos L Jr, Wade J, Lin F, Condie BA, Hanrieder J, Hoffman R. Designer antibacterial peptides kill fluoroquinolone-resistant clinical isolates. J. Med. Chem. 2005; (in press) DOI:jm050347i.
102. Balaban N, Gov Y, Giacometti A, Cirioni O, Ghiselli R, Mochegiani F, Orlando F, D'Amato G, Saba V, Scalise G, Bernes S, Mor A. A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci. Antimicrob. Agents Chemother. 48: 2544-2550